NAD-boosting treatment shows no Parkinson's benefit in yearlong trial
A major clinical trial involving 410 people with early Parkinson's disease has found no clinical benefit from nicotinamide riboside (NR), a compound that increases cellular levels of nicotinamide adenine dinucleotide (NAD). The findings are published in JAMA.
This is a short extract from a report by Medical Xpress. The full text stays with the publisher — follow the link to read it there.
Read at source
